» Articles » PMID: 17911384

ALK5- and TGFBR2-independent Role of ALK1 in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2007 Oct 4
PMID 17911384
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

ALK1 belongs to the type I receptor family for transforming growth factor-beta family ligands. Heterozygous ALK1 mutations cause hereditary hemorrhagic telangiectasia type 2 (HHT2), a multisystemic vascular disorder. Based largely on in vitro studies, TGF-beta1 has been considered as the most likely ALK1 ligand related to HHT, yet the identity of the physiologic ALK1 ligand remains controversial. In cultured endothelial cells, ALK1 and another TGF-beta type I receptor, ALK5, regulate angiogenesis by controlling TGF-beta signal transduction, and ALK5 is required for ALK1 signaling. However, the extent to which such interactions between these 2 receptors play a role in pathogenesis of HHT is unknown. We directly addressed these issues in vivo by comparing the phenotypes of mice in which the Alk1, Alk5, or Tgfbr2 gene was conditionally deleted in restricted vascular endothelia using a novel endothelial Cre transgenic line. Alk1-conditional deletion resulted in severe vascular malformations mimicking all pathologic features of HHT. Yet Alk5- or Tgfbr2-conditional deletion in mice, or Alk5 inhibition in zebrafish, did not affect vessel morphogenesis. These data indicate that neither ALK5 nor TGFBR2 is required for ALK1 signaling pertinent to the pathogenesis of HHT and suggest that HHT might not be a TGF-beta subfamily disease.

Citing Articles

From bench to bedside: murine models of inherited and sporadic brain arteriovenous malformations.

Ricciardelli A, Genet G, Genet N, McClugage 3rd S, Kan P, Hirschi K Angiogenesis. 2025; 28(2):15.

PMID: 39899215 PMC: 11790818. DOI: 10.1007/s10456-024-09953-5.


Sinomenine Ameliorated Microglial Activation and Neuropathic Pain After Chronic Constriction Injury Via TGF-β1/ALK5/Smad3 Signalling Pathway.

Ling L, Luo M, Yin H, Tian Y, Wang T, Zhang B J Cell Mol Med. 2024; 28(22):e70214.

PMID: 39586784 PMC: 11588427. DOI: 10.1111/jcmm.70214.


A non-genetic model of vascular shunts informs on the cellular mechanisms of formation and resolution of arteriovenous malformations.

Ouarne M, Pena A, Ramalho D, Conchinha N, Costa T, Enjalbert R Cardiovasc Res. 2024; 120(15):1967-1984.

PMID: 39308243 PMC: 11629978. DOI: 10.1093/cvr/cvae160.


Evaluation of AAV Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy.

Yadav A, Liang R, Press K, Schmidt A, Shabani Z, Leng K Transl Stroke Res. 2024; .

PMID: 38977637 DOI: 10.1007/s12975-024-01275-4.


Evaluation of Aav Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy.

Yadav A, Liang R, Press K, Schmidt A, Shabani Z, Leng K Res Sq. 2024; .

PMID: 38947073 PMC: 11213183. DOI: 10.21203/rs.3.rs-4469011/v1.


References
1.
Chytil A, Magnuson M, Wright C, Moses H . Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis. 2002; 32(2):73-5. DOI: 10.1002/gene.10046. View

2.
Wieser R, Wrana J, Massague J . GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J. 1995; 14(10):2199-208. PMC: 398326. DOI: 10.1002/j.1460-2075.1995.tb07214.x. View

3.
Abdalla S, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M . Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet. 2000; 9(8):1227-37. DOI: 10.1093/hmg/9.8.1227. View

4.
Alva J, Zovein A, Monvoisin A, Murphy T, Salazar A, Harvey N . VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn. 2006; 235(3):759-67. DOI: 10.1002/dvdy.20643. View

5.
Gallione C, Repetto G, Legius E, Rustgi A, Schelley S, Tejpar S . A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004; 363(9412):852-9. DOI: 10.1016/S0140-6736(04)15732-2. View